Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
JANUARY 2010
Volume 13, Issue 1
|
Selecting a contract research partner to help your biopharmaceutical process development
By: Amy Friesen
You've discovered a new biopharmaceutical product. You used milligrams of material for a proof-of-concept study, but now you need much more for doing additional pre-clinical work. |
|
The BC Centre for Excellence in HIV/AIDS: An agency of change
Compiled By: BC-CfE and Shawn Lawrence
The BC Centre for Excellence in HIV/AIDS (BC-CfE) was first established by the BC Minister of Health in 1992. At that time, there was much anxiety and little clarity on what was the best approach to manage the HIV epidemic. |
|
Biotherapeutics - The promise of biological innovation
By: Mike Pettapiece
Biotherapeutic therapies are sometimes referred to as biological smart bombs. Such treatments are organic molecules that can zero in on a diseased area without harming normal, healthy tissues. That makes them more patient-friendly than a more invasive treatment regimen, such as that provided by radiotherapy or chemotherapy. |
|
Expect More "Biosimilars" On The Market In Canada
By Louisa Pontrelli and Noel Courage
As more innovator patents for biologics approach expiry, the interest in developing “generic versions” or “copies” of these biologics, known as “biosimilars” will increase. |
|
A Biotech Finds Its X-Factor For Survival
By Shawn Lawrence
Xenon Pharmaceuticals president and CEO Simon Pimstone Life science companies are always on the lookout for new sources of a capital. A growing trend right now has seen many biotech firms allying themselves with major pharmaceutical companies. This has become a major step to ensuring their survival. |
